Cargando…

Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate

INTRODUCTION: While there has been considerable progress in the development of vaccines against SARS-CoV-2, largely based on the S (spike) protein of the virus, less progress has been made with vaccines delivering different viral antigens with cross-reactive potential. METHODS: In an effort to devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdiguero, Beatriz, Marcos-Villar, Laura, López-Bravo, María, Sánchez-Cordón, Pedro J., Zamora, Carmen, Valverde, José Ramón, Sorzano, Carlos Óscar S., Sin, Laura, Álvarez, Enrique, Ramos, Manuel, Del Val, Margarita, Esteban, Mariano, Gómez, Carmen Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316789/ https://www.ncbi.nlm.nih.gov/pubmed/37404819 http://dx.doi.org/10.3389/fimmu.2023.1160065

Ejemplares similares

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C
por: Perdiguero, Beatriz, et al.
Publicado: (2013)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses
por: Falqui, Michela, et al.
Publicado: (2023)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Involvement of the Cellular Phosphatase DUSP1 in Vaccinia Virus Infection
por: Cáceres, Ana, et al.
Publicado: (2013)

Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
por: Lázaro-Frías, Adrián, et al.
Publicado: (2022)

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

A Human Multi-Epitope Recombinant Vaccinia Virus as a Universal T Cell Vaccine Candidate against Influenza Virus
por: Goodman, Alan G., et al.
Publicado: (2011)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses
por: Usero, Lorena, et al.
Publicado: (2023)

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
por: García-Arriaza, Juan, et al.
Publicado: (2021)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2012)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
por: Vijayan, Aneesh, et al.
Publicado: (2015)

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
por: Raman, Suresh C., et al.
Publicado: (2019)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Patched-Related Is Required for Proper Development of Embryonic Drosophila Nervous System
por: Bolatto, Carmen, et al.
Publicado: (2022)

Activation of NF-kB Pathway by Virus Infection Requires Rb Expression
por: Garcia, Maria A., et al.
Publicado: (2009)

Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: Guardo, Alberto C., et al.
Publicado: (2018)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

The Evolution of Poxvirus Vaccines
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2015)

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection
por: Pérez, Patricia, et al.
Publicado: (2022)

Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein
por: Falivene, Juliana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5vrrcbqtsb14gc8qrbj0ml7fjp